|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As part of the Reproducibility Project: Cancer Biology we published a Registered Report (Lesnik et al., 2016) that described how we intended to replicate selected experiments from the paper 'Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET' (Peinado et al., 2012).Here we report the results.
|
30526855 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on our results, we conclude that both EGFR and MET receptors might be effective targets in melanoma therapy.
|
29719603 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma.
|
29426936 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, these findings support the clinical evaluation of MET-directed targeted therapy to circumvent resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma.
|
28147313 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In rare tumour types we observed, amongst others, a predicted overexpression rate of 55% of samples for CD22 and 55% for ENPP3 in adrenocortical carcinomas, 81% for CD74 and 81% for FGFR3 in osteosarcomas, and 95% for c-MET in uveal melanomas.
|
29045509 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies indicated that MET in tumor-derived exosomes facilitates metastatic niche formation and metastasis in malignant melanoma.
|
28064454 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we identified SPINT2 (serine peptidase inhibitor Kunitz type 2), a proteolytic inhibitor of hepatocyte growth factor activator (HGFA), which has a significant role in the suppression of the HGF-MET pathway and malignant melanoma progression.
|
25910030 |
2015 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The MET proto-oncogene (MET) tyrosine kinase receptor promotes many of these cellular processes, but while MET is often overexpressed in melanoma, the mechanism driving this overexpression is unknown.
|
25531327 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET fusion kinases thus provide a potential therapeutic target for a rare subset of melanoma for which currently no targeted therapeutic options currently exist.
|
26013381 |
2015 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, MET mutations were detected in 12% of Irish cases, whereas none of the Belgian patients harbored these mutations, and Irish patients significantly more often (P=0.027) had PIK3R1-mutant (33%) melanoma versus 17% of Belgian cases.
|
25746038 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we identify lineage-specific enhancers at the MET locus for multiple common tumor types, including a melanoma lineage-specific enhancer 63 kb downstream from the MET TSS.
|
24443471 |
2014 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further analyses on appropriately powered subsets are needed to determine the prognostic and predictive significance of MET in vemurafenib-treated melanoma.
|
23802768 |
2013 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma.
|
22763439 |
2012 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ectopic overexpression of miR-31 in various melanoma cell lines inhibited cell migration and invasion. miR-31 targets include oncogenic kinases such as SRC, MET, NIK (MAP3K14) and the melanoma specific oncogene RAB27a.
|
22948084 |
2012 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Screening of a set of independently isolated melanoma cell lines from other patients confirmed this association between expression of high levels of MET and of VEGF-C and PDGF-C.
|
22570180 |
2012 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RTK analysis of all CCS/MM samples showed activation of short-form (sf) recepteur d'origine nantais (RON) RTK and of PDGFRB, MET, and HER3.
|
22045652 |
2012 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that melanoma cells sense hypoxia-enhancing expression/activation of the Met proto-oncogene, which drives a motogenic escape program.
|
21703345 |
2011 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We identified five RTKs that were active in almost every one of the melanoma tissue specimens and cell lines, including two previously unreported receptors, insulin-like growth factor receptor 1 (IGF-1R) and macrophage-stimulating protein receptor (MSPR), in addition to three receptors (vascular endothelial growth factor receptor, fibroblast growth factor receptor, and hepatocyte growth factor receptor) known to be autocrine activated in melanoma.
|
21654344 |
2011 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET oncogene inhibition as a potential target of therapy for uveal melanomas.
|
20164465 |
2010 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET expression is rarely detected in primary human melanoma but is frequently observed in metastatic disease.
|
19422607 |
2009 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These observations strengthen the roles of MITF and MET in melanoma development.
|
17371876 |
2007 |